{"result": {"id": "b1e49a75-14ba-4d90-b8f2-d49df08df5fa", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CHINESE MEDICAL ASSOCIATION<|>ORGANIZATION<|>The Chinese Medical Association is involved in publishing medical guidelines and research in China\")\n##\n(\"entity\"<|>CHINESE SOCIETY OF CARDIOLOGY<|>ORGANIZATION<|>The Chinese Society of Cardiology publishes research on cardiovascular diseases in China\")\n##\n(\"entity\"<|>GLOBAL BURDEN OF DISEASE STUDY<|>ORGANIZATION<|>The Global Burden of Disease Study provides comprehensive data on disease burden worldwide\")\n##\n(\"entity\"<|>ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL<|>EVENT<|>A clinical trial studying cardiac outcomes with lipid-lowering treatments\")\n##\n(\"entity\"<|>ASCOT-LLA<|>EVENT<|>The lipid-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial\")\n##\n(\"entity\"<|>CHINA<|>GEO<|>Country where many of the studies and guidelines were conducted\")\n##\n(\"relationship\"<|>CHINESE MEDICAL ASSOCIATION DIABETES SOCIETY<|>CHINESE MEDICAL ASSOCIATION<|>The Diabetes Society is part of the Chinese Medical Association<|>8)\n##\n(\"relationship\"<|>CHINESE MEDICAL ASSOCIATION GERIATRICS SOCIETY<|>CHINESE MEDICAL ASSOCIATION<|>The Geriatrics Society is part of the Chinese Medical Association<|>8)\n##\n(\"relationship\"<|>CHINESE SOCIETY OF CARDIOLOGY<|>CHINESE MEDICAL ASSOCIATION<|>The Society of Cardiology is part of the Chinese Medical Association<|>8)\n##\n(\"relationship\"<|>ZHANG G<|>GLOBAL BURDEN OF DISEASE STUDY<|>Zhang G contributed to the Global Burden of Disease Study<|>6)\n##\n(\"relationship\"<|>YU C<|>GLOBAL BURDEN OF DISEASE STUDY<|>Yu C contributed to the Global Burden of Disease Study<|>6)\n##\n(\"relationship\"<|>ZHOU M<|>GLOBAL BURDEN OF DISEASE STUDY<|>Zhou M contributed to the Global Burden of Disease Study<|>6)\n##\n(\"relationship\"<|>SEVER PS<|>ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL<|>Sever PS was involved in the Anglo-Scandinavian Cardiac Outcomes Trial<|>7)\n##\n(\"relationship\"<|>DAHLÖF B<|>ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL<|>Dahlöf B was involved in the Anglo-Scandinavian Cardiac Outcomes Trial<|>7)\n##\n(\"relationship\"<|>POULTER NR<|>ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL<|>Poulter NR was involved in the Anglo-Scandinavian Cardiac Outcomes Trial<|>7)\n##\n(\"relationship\"<|>ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL<|>ASCOT-LLA<|>ASCOT-LLA was part of the Anglo-Scandinavian Cardiac Outcomes Trial<|>9)\n##\n(\"relationship\"<|>CHINESE MEDICAL ASSOCIATION<|>CHINA<|>The Chinese Medical Association is based in China<|>8)\n##\n(\"relationship\"<|>CHINESE SOCIETY OF CARDIOLOGY<|>CHINA<|>The Chinese Society of Cardiology is based in China<|>8)\n##\n(\"relationship\"<|>NATIONAL CENTER FOR GERIATRICS<|>CHINA<|>The National Center for Geriatrics is based in China<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559045, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 833, "prompt_tokens": 5862, "total_tokens": 6695, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3712}, "prompt_cache_hit_tokens": 3712, "prompt_cache_miss_tokens": 2150}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: randomizedcon- trolledtrials[J]. ComplementTherMed,2015,23(3) :494-504.\n[334]  ZhangSF, MaoXJ, JiangWM, etal. QianYangYuYinGran- uleprotects againsthypertension-induced renalinjury by epige- netic mechanism  linked  to nicotinamide N-methyltransferase (NNMT) expression[J]. J Ethnopharmacol,2020,255:112738.\n[335]  Zhu Y, HuangJJ, ZhangXX, etal. QingGanZiShenTangal- leviatesadipose tissue dysfunction with up-regulation of SIRT1 in spontaneously hypertensive rat[J].  Biomed Pharmacother,  2018,105:246-255.\n[336]  中华医学会糖尿病学分会.  中国 2型糖尿病防治指南(2020年 版)[J]. 中华糖尿病杂志 ,2021,13(4) :315-409.\n[337]  AmericanDiabetesAssociationProfessionalPracticeCommittee.\n　9. Pharmacologicapproachestoglycemictreatment: standardsof carein diabetes-2024[J]. Diabetes Care, 2024, 47(Suppl 1) :\n\n\n\nS158-S178.\n[338]  国家老年医学中心 , 中华医学会老年医学分会 , 中国老年保健协 会糖尿病专业委员会.  中国老年糖尿病诊疗指南(2021年版) [J]. 中华糖尿病杂志 ,2021,13(1) :14-46.\n[339]  刘军 ,王薇 ,刘静 ,等.  门诊高血压病患者合并心血管病危险因素  及血压控制现况[J]. 中华心血管病杂志 , 2013, 41(12) : 1050- 1054.\n[340]  ZhangG, Yu C, Zhou M, etal. Burden ofischaemicheartdis- easeand attributable risk factors in China from 1990 to 2015:  findingsfrom the globalburden ofdisease2015 study[J]. BMC CardiovascDisord,2018,18(1) :18.\n[341]  Mihaylova B, Emberson J, BlackwellL, et al.  The effects of loweringLDL cholesterol with statin therapy in people at low  risk ofvasculardisease: meta-analysisofindividualdatafrom 27 randomised trials[J]. Lancet,2012,380(9841) :581-590.\n[342]  Cannon CP, BlazingMA, GiuglianoRP, etal. Ezetimibeadded to statin therapy after acute coronary syndromes[J]. N EnglJ Med,2015,372(25) :2387-2397.\n[343]  SabatineMS, GiuglianoRP, KeechAC, etal. Evolocumab and clinicaloutcomes in patients with cardiovascular disease[J]. N  EnglJ Med,2017,376(18) :1713-1722.\n[344]  SeverPS, Dahl?fB, PoulterNR, etal. Prevention ofcoronary and strokeeventswith atorvastatin in hypertensivepatientswho have average or lower-than-average cholesterol concentrations,  in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA) : a multicentre randomised controlled trial [J]. Lancet,2003,361(9364) :1149-1158.\n[345]  YusufS, LonnE, PaisP, etal. Blood-pressureand cholesterol loweringin personswithoutcardiovasculardisease[J]. N EnglJ Med,2016,374(21) :2032-2043.\n[346]  YusufS, JosephP, DansA, etal. Polypillwithorwithoutaspi- rin in personswithoutcardiovasculardisease[J]. N EnglJ Med,  2021,384(3) :216-228.\n[347]  SeverPS, PoulterNR, DahlofB, etal. TheAnglo-Scandinavian cardiacoutcomestriallipidlowering arm: extended observations 2 yearsaftertrialclosure[J]. EurHeartJ,2008,29(4) :499-508.\n[348]  中国血脂管理指南修订联合专家委员会.  中国血脂管理指南 (2023年)[J]. 中国循环杂志 ,2023,38(3) :237-271.\n[349]  BaigentC, BlackwellL, CollinsR, etal. Aspirinintheprimary and secondarypreventionofvasculardisease: collaborativemeta- analysisofindividualparticipantdatafrom randomisedtrials[J].   Lancet,2009,373(9678) :1849-1860.\n[350]  SmithSCJr\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>ZHANG SF<|>PERSON<|>Zhang SF is a researcher involved in studying hypertension-induced renal injury and NNMT expression)\n##\n(\"entity\"<|>MAO XJ<|>PERSON<|>Mao XJ is a researcher involved in studying hypertension-induced renal injury and NNMT expression)\n##\n(\"entity\"<|>JIANG WM<|>PERSON<|>Jiang WM is a researcher involved in studying hypertension-induced renal injury and NNMT expression)\n##\n(\"entity\"<|>ZHU Y<|>PERSON<|>Zhu Y is a researcher involved in studying adipose tissue dysfunction in hypertensive rats)\n##\n(\"entity\"<|>HUANG JJ<|>PERSON<|>Huang JJ is a researcher involved in studying adipose tissue dysfunction in hypertensive rats)\n##\n(\"entity\"<|>ZHANG XX<|>PERSON<|>Zhang XX is a researcher involved in studying adipose tissue dysfunction in hypertensive rats)\n##\n(\"entity\"<|>CHINESE MEDICAL ASSOCIATION DIABETES SOCIETY<|>ORGANIZATION<|>The Chinese Medical Association Diabetes Society published guidelines for the prevention and treatment of type 2 diabetes in China)\n##\n(\"entity\"<|>AMERICAN DIABETES ASSOCIATION PROFESSIONAL PRACTICE COMMITTEE<|>ORGANIZATION<|>The American Diabetes Association Professional Practice Committee published standards of care in diabetes for 2024)\n##\n(\"entity\"<|>NATIONAL CENTER FOR GERIATRICS<|>ORGANIZATION<|>The National Center for Geriatrics published guidelines for the diagnosis and treatment of diabetes in elderly Chinese patients)\n##\n(\"entity\"<|>CHINESE MEDICAL ASSOCIATION GERIATRICS SOCIETY<|>ORGANIZATION<|>The Chinese Medical Association Geriatrics Society collaborated on guidelines for elderly diabetes patients)\n##\n(\"entity\"<|>CHINESE GERIATRIC DIABETES ASSOCIATION<|>ORGANIZATION<|>The Chinese Geriatric Diabetes Association collaborated on guidelines for elderly diabetes patients)\n##\n(\"entity\"<|>LIU JUN<|>PERSON<|>Liu Jun is a researcher involved in studying hypertension and cardiovascular risk factors)\n##\n(\"entity\"<|>WANG WEI<|>PERSON<|>Wang Wei is a researcher involved in studying hypertension and cardiovascular risk factors)\n##\n(\"entity\"<|>LIU JING<|>PERSON<|>Liu Jing is a researcher involved in studying hypertension and cardiovascular risk factors)\n##\n(\"entity\"<|>ZHANG G<|>PERSON<|>Zhang G is a researcher involved in studying the burden of ischaemic heart disease in China)\n##\n(\"entity\"<|>YU C<|>PERSON<|>Yu C is a researcher involved in studying the burden of ischaemic heart disease in China)\n##\n(\"entity\"<|>ZHOU M<|>PERSON<|>Zhou M is a researcher involved in studying the burden of ischaemic heart disease in China)\n##\n(\"entity\"<|>MIHAYLOVA B<|>PERSON<|>Mihaylova B is a researcher involved in studying the effects of LDL cholesterol lowering with statin therapy)\n##\n(\"entity\"<|>EMBERSON J<|>PERSON<|>Emberson J is a researcher involved in studying the effects of LDL cholesterol lowering with statin therapy)\n##\n(\"entity\"<|>BLACKWELL L<|>PERSON<|>Blackwell L is a researcher involved in studying the effects of LDL cholesterol lowering with statin therapy)\n##\n(\"entity\"<|>CANNON CP<|>PERSON<|>Cannon CP is a researcher involved in studying ezetimibe added to statin therapy after acute coronary syndromes)\n##\n(\"entity\"<|>BLAZING MA<|>PERSON<|>Blazing MA is a researcher involved in studying ezetimibe added to statin therapy after acute coronary syndromes)\n##\n(\"entity\"<|>GIUGLIANO RP<|>PERSON<|>Giugliano RP is a researcher involved in studying ezetimibe added to statin therapy after acute coronary syndromes)\n##\n(\"entity\"<|>SABATINE MS<|>PERSON<|>Sabatine MS is a researcher involved in studying evolocumab and clinical outcomes in patients with cardiovascular disease)\n##\n(\"entity\"<|>KEECH AC<|>PERSON<|>Keech AC is a researcher involved in studying evolocumab and clinical outcomes in patients with cardiovascular disease)\n##\n(\"entity\"<|>SEVER PS<|>PERSON<|>Sever PS is a researcher involved in studying the prevention of coronary and stroke events with atorvastatin in hypertensive patients)\n##\n(\"entity\"<|>DAHLÖF B<|>PERSON<|>Dahlöf B is a researcher involved in studying the prevention of coronary and stroke events with atorvastatin in hypertensive patients)\n##\n(\"entity\"<|>POULTER NR<|>PERSON<|>Poulter NR is a researcher involved in studying the prevention of coronary and stroke events with atorvastatin in hypertensive patients)\n##\n(\"entity\"<|>YUSUF S<|>PERSON<|>Yusuf S is a researcher involved in studying blood-pressure and cholesterol lowering in persons without cardiovascular disease)\n##\n(\"entity\"<|>LONN E<|>PERSON<|>Lonn E is a researcher involved in studying blood-pressure and cholesterol lowering in persons without cardiovascular disease)\n##\n(\"entity\"<|>PAIS P<|>PERSON<|>Pais P is a researcher involved in studying blood-pressure and cholesterol lowering in persons without cardiovascular disease)\n##\n(\"entity\"<|>JOSEPH P<|>PERSON<|>Joseph P is a researcher involved in studying polypill with or without aspirin in persons without cardiovascular disease)\n##\n(\"entity\"<|>DANS A<|>PERSON<|>Dans A is a researcher involved in studying polypill with or without aspirin in persons without cardiovascular disease)\n##\n(\"entity\"<|>BAIGENT C<|>PERSON<|>Baigent C is a researcher involved in studying aspirin in the primary and secondary prevention of vascular disease)\n##\n(\"entity\"<|>COLLINS R<|>PERSON<|>Collins R is a researcher involved in studying aspirin in the primary and secondary prevention of vascular disease)\n##\n(\"entity\"<|>CHINA LIPID MANAGEMENT GUIDELINE REVISION EXPERT COMMITTEE<|>ORGANIZATION<|>The China Lipid Management Guideline Revision Expert Committee published guidelines for lipid management in China)\n##\n(\"entity\"<|>SMITH SC JR<|>PERSON<|>Smith SC Jr is a researcher involved in cardiovascular studies)\n##\n(\"relationship\"<|>ZHANG SF<|>MAO XJ<|>Zhang SF and Mao XJ collaborated on research about hypertension-induced renal injury<|>5)\n##\n(\"relationship\"<|>ZHANG SF<|>JIANG WM<|>Zhang SF and Jiang WM collaborated on research about hypertension-induced renal injury<|>5)\n##\n(\"relationship\"<|>MAO XJ<|>JIANG WM<|>Mao XJ and Jiang WM collaborated on research about hypertension-induced renal injury<|>5)\n##\n(\"relationship\"<|>ZHU Y<|>HUANG JJ<|>Zhu Y and Huang JJ collaborated on research about adipose tissue dysfunction in hypertensive rats<|>5)\n##\n(\"relationship\"<|>ZHU Y<|>ZHANG XX<|>Zhu Y and Zhang XX collaborated on research about adipose tissue dysfunction in hypertensive rats<|>5)\n##\n(\"relationship\"<|>HUANG JJ<|>ZHANG XX<|>Huang JJ and Zhang XX collaborated on research about adipose tissue dysfunction in hypertensive rats<|>5)\n##\n(\"relationship\"<|>LIU JUN<|>WANG WEI<|>Liu Jun and Wang Wei collaborated on research about hypertension and cardiovascular risk factors<|>5)\n##\n(\"relationship\"<|>LIU JUN<|>LIU JING<|>Liu Jun and Liu Jing collaborated on research about hypertension and cardiovascular risk factors<|>5)\n##\n(\"relationship\"<|>WANG WEI<|>LIU JING<|>Wang Wei and Liu Jing collaborated on research about hypertension and cardiovascular risk factors<|>5)\n##\n(\"relationship\"<|>ZHANG G<|>YU C<|>Zhang G and Yu C collaborated on research about the burden of ischaemic heart disease in China<|>5)\n##\n(\"relationship\"<|>ZHANG G<|>ZHOU M<|>Zhang G and Zhou M collaborated on research about the burden of ischaemic heart disease in China<|>5)\n##\n(\"relationship\"<|>YU C<|>ZHOU M<|>Yu C and Zhou M collaborated on research about the burden of ischaemic heart disease in China<|>5)\n##\n(\"relationship\"<|>MIHAYLOVA B<|>EMBERSON J<|>Mihaylova B and Emberson J collaborated on research about the effects of LDL cholesterol lowering with statin therapy<|>5)\n##\n(\"relationship\"<|>MIHAYLOVA B<|>BLACKWELL L<|>Mihaylova B and Blackwell L collaborated on research about the effects of LDL cholesterol lowering with statin therapy<|>5)\n##\n(\"relationship\"<|>EMBERSON J<|>BLACKWELL L<|>Emberson J and Blackwell L collaborated on research about the effects of LDL cholesterol lowering with statin therapy<|>5)\n##\n(\"relationship\"<|>CANNON CP<|>BLAZING MA<|>Cannon CP and Blazing MA collaborated on research about ezetimibe added to statin therapy after acute coronary syndromes<|>5)\n##\n(\"relationship\"<|>CANNON CP<|>GIUGLIANO RP<|>Cannon CP and Giugliano RP collaborated on research about ezetimibe added to statin therapy after acute coronary syndromes<|>5)\n##\n(\"relationship\"<|>BLAZING MA<|>GIUGLIANO RP<|>Blazing MA and Giugliano RP collaborated on research about ezetimibe added to statin therapy after acute coronary syndromes<|>5)\n##\n(\"relationship\"<|>SABATINE MS<|>GIUGLIANO RP<|>Sabatine MS and Giugliano RP collaborated on research about evolocumab and clinical outcomes in patients with cardiovascular disease<|>5)\n##\n(\"relationship\"<|>SABATINE MS<|>KEECH AC<|>Sabatine MS and Keech AC collaborated on research about evolocumab and clinical outcomes in patients with cardiovascular disease<|>5)\n##\n(\"relationship\"<|>GIUGLIANO RP<|>KEECH AC<|>Giugliano RP and Keech AC collaborated on research about evolocumab and clinical outcomes in patients with cardiovascular disease<|>5)\n##\n(\"relationship\"<|>SEVER PS<|>DAHLÖF B<|>Sever PS and Dahlöf B collaborated on research about the prevention of coronary and stroke events with atorvastatin in hypertensive patients<|>5)\n##\n(\"relationship\"<|>SEVER PS<|>POULTER NR<|>Sever PS and Poulter NR collaborated on research about the prevention of coronary and stroke events with atorvastatin in hypertensive patients<|>5)\n##\n(\"relationship\"<|>DAHLÖF B<|>POULTER NR<|>Dahlöf B and Poulter NR collaborated on research about the prevention of coronary and stroke events with atorvastatin in hypertensive patients<|>5)\n##\n(\"relationship\"<|>YUSUF S<|>LONN E<|>Yusuf S and Lonn E collaborated on research about blood-pressure and cholesterol lowering in persons without cardiovascular disease<|>5)\n##\n(\"relationship\"<|>YUSUF S<|>PAIS P<|>Yusuf S and Pais P collaborated on research about blood-pressure and cholesterol lowering in persons without cardiovascular disease<|>5)\n##\n(\"relationship\"<|>LONN E<|>PAIS P<|>Lonn E and Pais P collaborated on research about blood-pressure and cholesterol lowering in persons without cardiovascular disease<|>5)\n##\n(\"relationship\"<|>YUSUF S<|>JOSEPH P<|>Yusuf S and Joseph P collaborated on research about polypill with or without aspirin in persons without cardiovascular disease<|>5)\n##\n(\"relationship\"<|>YUSUF S<|>DANS A<|>Yusuf S and Dans A collaborated on research about polypill with or without aspirin in persons without cardiovascular disease<|>5)\n##\n(\"relationship\"<|>JOSEPH P<|>DANS A<|>Joseph P and Dans A collaborated on research about polypill with or without aspirin in persons without cardiovascular disease<|>5)\n##\n(\"relationship\"<|>BAIGENT C<|>BLACKWELL L<|>Baigent C and Blackwell L collaborated on research about aspirin in the primary and secondary prevention of vascular disease<|>5)\n##\n(\"relationship\"<|>BAIGENT C<|>COLLINS R<|>Baigent C and Collins R collaborated on research about aspirin in the primary and secondary prevention of vascular disease<|>5)\n##\n(\"relationship\"<|>BLACKWELL L<|>COLLINS R<|>Blackwell L and Collins R collaborated on research about aspirin in the primary and secondary prevention of vascular disease<|>5)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_b5df0f556efca595bcbb35c2a76514ed4e1fbfd6f9737f4a1b8c62d7ebc57124_v2"}